Boston Scientific Corporation (BSX) Shares Bought by Pioneer Investment Management Inc.

Pioneer Investment Management Inc. raised its position in Boston Scientific Corporation (NYSE:BSX) by 1.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,974,820 shares of the medical equipment provider’s stock after buying an additional 36,143 shares during the period. Pioneer Investment Management Inc. owned approximately 0.14% of Boston Scientific Corporation worth $54,742,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Guardian Life Insurance Co. of America raised its stake in shares of Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 49 shares during the period. First Personal Financial Services raised its stake in shares of Boston Scientific Corporation by 0.9% in the first quarter. First Personal Financial Services now owns 9,107 shares of the medical equipment provider’s stock worth $226,000 after buying an additional 80 shares during the period. Cleararc Capital Inc. raised its stake in shares of Boston Scientific Corporation by 0.8% in the first quarter. Cleararc Capital Inc. now owns 33,322 shares of the medical equipment provider’s stock worth $829,000 after buying an additional 251 shares during the period. Bronfman E.L. Rothschild L.P. raised its stake in shares of Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 338 shares during the period. Finally, Checchi Capital Advisers LLC raised its stake in shares of Boston Scientific Corporation by 2.6% in the first quarter. Checchi Capital Advisers LLC now owns 13,553 shares of the medical equipment provider’s stock worth $337,000 after buying an additional 349 shares during the period. Institutional investors own 91.62% of the company’s stock.

Boston Scientific Corporation (BSX) traded up 0.94% during midday trading on Friday, hitting $26.89. The stock had a trading volume of 5,850,175 shares. Boston Scientific Corporation has a 12-month low of $19.67 and a 12-month high of $28.51. The company has a 50-day moving average price of $27.16 and a 200-day moving average price of $26.15. The company has a market cap of $36.90 billion, a price-to-earnings ratio of 48.10 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the previous year, the business earned $0.27 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. Equities analysts anticipate that Boston Scientific Corporation will post $1.26 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Boston Scientific Corporation (BSX) Shares Bought by Pioneer Investment Management Inc.” was first published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/boston-scientific-corporation-bsx-position-increased-by-pioneer-investment-management-inc-updated.html.

A number of brokerages have issued reports on BSX. J P Morgan Chase & Co reiterated an “overweight” rating and set a $31.00 price target (up from $27.00) on shares of Boston Scientific Corporation in a research note on Wednesday, June 28th. Zacks Investment Research lowered shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. Royal Bank Of Canada restated a “buy” rating and set a $31.00 target price on shares of Boston Scientific Corporation in a research note on Wednesday, July 12th. Wells Fargo & Company restated an “outperform” rating and set a $31.00 target price (up from $29.50) on shares of Boston Scientific Corporation in a research note on Friday, June 16th. Finally, BidaskClub upgraded shares of Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 10th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $30.06.

In other news, CFO Daniel J. Brennan sold 92,158 shares of the business’s stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $27.48, for a total value of $2,532,501.84. Following the completion of the sale, the chief financial officer now directly owns 235,421 shares in the company, valued at approximately $6,469,369.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael P. Phalen sold 15,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $27.25, for a total value of $422,375.00. The disclosure for this sale can be found here. Insiders sold a total of 207,625 shares of company stock valued at $5,686,383 over the last quarter. Company insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply